

Clinical Trial Activity in Ontario Between 2015–2022

BRAIN AND/OR NERVES

Phase I using a diabetes drug for brain repair in children with multiple sclerosis: Toronto (Active)

Phase II using stem cells for multiple sclerosis: Complete

Phase II using a diabetes drug for brain repair in children with cerebral palsy: Toronto (Active)

Phase III using a diabetes drug to stimulate brain repair for malignant brain tumours: Complete

GENETIC DISORDERS

Phase I using genetically modified stem cells for Fabry disease: Complete

BLOOD

Phase I using cell therapy to help patients recover from radiation/chemotherapies for the treatment of leukemia: Pending 2022–23

LIVER

Phase II–III using stem cells to induce tolerance in recipients of liver transplants: Ottawa and Toronto (Active)

JOINTS

Phase I–II using stem cells for knee osteoarthritis: Complete

Phase III using a cartilage tissue implant grown from patient's cells: Complete

BURNS

Phase I using stem cells developed from a patient's surgically removed burned tissue to improve wound healing: Active

MUSCLE

Phase I using a drug to restore muscle regeneration in children with muscular dystrophy: Pending 2022–23

HEART

Phase I using stem cells to repair heart damage: Pending 2022–23

Phase II using genetically modified stem cells following a heart attack: Complete

Phase II using stem cells for advanced heart failure with left ventricular assist device: Complete

Phase II using cell therapy combined with coronary artery bypass grafting to treat heart failure: Complete

LUNG

Phase I using stem cells for bronchopulmonary dysplasia in pre-term infants: Active

Phase II using genetically modified stem cells for pulmonary arterial hypertension: London, Ottawa, Toronto and Hamilton (Active)

CRITICAL CARE

Phase I cell therapy for septic shock: Complete

Phase II cell therapy for septic shock: Pending 2021

Phase I cell therapy for COVID-19 related acute respiratory distress syndrome: Ottawa, Toronto, Montreal (Active)

All trials led by OIRM investigators

All trials sponsored/funded by some or all of the following: UHN, Ottawa Hospital Research Institute, SickKids, Dr. Gary Levy, Dr. Jas Chahal, Histogenics, CIHR, Stem Cell Network, Ozmosis Research Inc., Dr. Annetine Gelijns, National Heart, Lung and Blood Institute, Northern Therapeutics and OIRM.

